MedPath

A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients

Not Applicable
Completed
Conditions
HIV Infections
Registration Number
NCT00002426
Lead Sponsor
Gilead Sciences
Brief Summary

The purpose of this study is to see if it is safe and effective to give an experimental anti-HIV drug, adefovir dipivoxil (ADV), in combination with other anti-HIV drugs (HAART) to patients who have a viral load (level of HIV in the blood) between 50 and 400 copies/ml.

Detailed Description

Patients are randomized to 1 of 2 arms in a 2:1 ratio. Approximately 260 patients receive ADV and approximately 130 patients receive placebo. Patients receive ADV or placebo in addition to L-carnitine and their current stable HAART regimen. Each patient receives blinded study medication for 48 weeks and is evaluated at Weeks 16, 24, and 48. Patients who reach the primary endpoint of virologic failure prior to Week 48 may continue blinded study medication or receive open-label ADV at the investigator's discretion. In both cases, patients continue their study visits as per the original visit schedule. Virologic failure is defined as 2 consecutive HIV-1 RNA measurements, after baseline, above 400 copies/ml (measured by the Roche Amplicor HIV-1 Monitor UltraSensitive assay) drawn at least 14 days apart. All patients who complete study visits without treatment-limiting ADV toxicity may continue open-label ADV in the Maintenance Phase at the discretion of the principal investigator.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
390
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (49)

Pacific Oaks Research

🇺🇸

Beverly Hills, California, United States

ViRx Inc

🇺🇸

Palm Springs, California, United States

Ctr for AIDS Research / Education and Service (CARES)

🇺🇸

Sacramento, California, United States

San Francisco Gen Hosp / UCSF AIDS Program

🇺🇸

San Francisco, California, United States

Kaiser Foundation Hospital

🇺🇸

San Francisco, California, United States

San Francisco VA Med Ctr

🇺🇸

San Francisco, California, United States

Blick Med Associates

🇺🇸

Stamford, Connecticut, United States

Georgetown Univ Med Ctr

🇺🇸

Washington, District of Columbia, United States

Dupont Circle Physicians Group

🇺🇸

Washington, District of Columbia, United States

George Washington Univ Med Ctr

🇺🇸

Washington, District of Columbia, United States

Scroll for more (39 remaining)
Pacific Oaks Research
🇺🇸Beverly Hills, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.